A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639
·
clinicaltrials.gov ↗
RECRUITING
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Hemoglobinopathy
Sickle Cell Disease
Interventions
DRUG:
Long-Term Follow-up Study of patients who received BEAM-101
Sponsor
Beam Therapeutics Inc.